EUR 140,63
Convertire valutaQuantità: 2 disponibili
Aggiungi al carrelloCondizione: NEW.
Da: GreatBookPricesUK, Woodford Green, Regno Unito
EUR 140,62
Convertire valutaQuantità: 10 disponibili
Aggiungi al carrelloCondizione: New.
Da: THE SAINT BOOKSTORE, Southport, Regno Unito
EUR 167,13
Convertire valutaQuantità: 1 disponibili
Aggiungi al carrelloHardback. Condizione: New. New copy - Usually dispatched within 4 working days. 720.
Da: Ria Christie Collections, Uxbridge, Regno Unito
EUR 170,45
Convertire valutaQuantità: 2 disponibili
Aggiungi al carrelloCondizione: New. In.
Da: Majestic Books, Hounslow, Regno Unito
EUR 173,64
Convertire valutaQuantità: 3 disponibili
Aggiungi al carrelloCondizione: New.
EUR 171,04
Convertire valutaQuantità: 2 disponibili
Aggiungi al carrelloCondizione: New. Harry Yang, Ph.D., is Vice President and Head of Biometrics at Fate Therapeutics. He has 25 years of experience across all aspects of drug research and development, from early target discovery, through pre-clinical, clinical, and CMC pro.
Da: Kennys Bookshop and Art Galleries Ltd., Galway, GY, Irlanda
Prima edizione
EUR 187,37
Convertire valutaQuantità: 2 disponibili
Aggiungi al carrelloCondizione: New. 2021. 1st Edition. Hardcover. . . . . .
Editore: Taylor & Francis Ltd Mär 2021, 2021
ISBN 10: 036702621X ISBN 13: 9780367026219
Lingua: Inglese
Da: AHA-BUCH GmbH, Einbeck, Germania
EUR 175,63
Convertire valutaQuantità: 2 disponibili
Aggiungi al carrelloBuch. Condizione: Neu. Neuware - This book concerns use of real world data (RWD) and real world evidence (RWE) to aid drug development across product cycle. RWD are healthcare data that are collected outside the constraints of conventual controlled randomized trials (CRTs); whereas RWE is the knowledge derived from aggregation and analysis of RWD.
EUR 179,21
Convertire valutaQuantità: 10 disponibili
Aggiungi al carrelloCondizione: New.
EUR 187,36
Convertire valutaQuantità: 1 disponibili
Aggiungi al carrelloHardcover. Condizione: Brand New. 1st edition. 178 pages. 9.75x6.50x0.75 inches. In Stock.
Da: Books Puddle, New York, NY, U.S.A.
EUR 197,65
Convertire valutaQuantità: 3 disponibili
Aggiungi al carrelloCondizione: New.
Da: Biblios, Frankfurt am main, HESSE, Germania
EUR 197,31
Convertire valutaQuantità: 3 disponibili
Aggiungi al carrelloCondizione: New.
EUR 232,73
Convertire valutaQuantità: 2 disponibili
Aggiungi al carrelloCondizione: New. 2021. 1st Edition. Hardcover. . . . . . Books ship from the US and Ireland.
Editore: Taylor & Francis Ltd, London, 2021
ISBN 10: 036702621X ISBN 13: 9780367026219
Lingua: Inglese
Da: Grand Eagle Retail, Fairfield, OH, U.S.A.
EUR 187,77
Convertire valutaQuantità: 1 disponibili
Aggiungi al carrelloHardcover. Condizione: new. Hardcover. Real-world evidence (RWE) has been at the forefront of pharmaceutical innovations. It plays an important role in transforming drug development from a process aimed at meeting regulatory expectations to an operating model that leverages data from disparate sources to aid business, regulatory, and healthcare decision making. Despite its many benefits, there is no single book systematically covering the latest development in the field.Written specifically for pharmaceutical practitioners, Real-World Evidence in Drug Development and Evaluation, presents a wide range of RWE applications throughout the lifecycle of drug product development. With contributions from experienced researchers in the pharmaceutical industry, the book discusses at length RWE opportunities, challenges, and solutions.FeaturesProvides the first book and a single source of information on RWE in drug developmentCovers a broad array of topics on outcomes- and value-based RWE assessments Demonstrates proper Bayesian application and causal inference for real-world data (RWD)Presents real-world use cases to illustrate the use of advanced analytics and statistical methods to generate insightsOffers a balanced discussion of practical RWE issues at hand and technical solutions suitable for practitioners with limited data science expertise This book concerns use of real world data (RWD) and real world evidence (RWE) to aid drug development across product cycle. RWD are healthcare data that are collected outside the constraints of conventual controlled randomized trials (CRTs); whereas RWE is the knowledge derived from aggregation and analysis of RWD. Shipping may be from multiple locations in the US or from the UK, depending on stock availability.
Editore: Taylor & Francis Ltd, London, 2021
ISBN 10: 036702621X ISBN 13: 9780367026219
Lingua: Inglese
Da: AussieBookSeller, Truganina, VIC, Australia
EUR 274,15
Convertire valutaQuantità: 1 disponibili
Aggiungi al carrelloHardcover. Condizione: new. Hardcover. Real-world evidence (RWE) has been at the forefront of pharmaceutical innovations. It plays an important role in transforming drug development from a process aimed at meeting regulatory expectations to an operating model that leverages data from disparate sources to aid business, regulatory, and healthcare decision making. Despite its many benefits, there is no single book systematically covering the latest development in the field.Written specifically for pharmaceutical practitioners, Real-World Evidence in Drug Development and Evaluation, presents a wide range of RWE applications throughout the lifecycle of drug product development. With contributions from experienced researchers in the pharmaceutical industry, the book discusses at length RWE opportunities, challenges, and solutions.FeaturesProvides the first book and a single source of information on RWE in drug developmentCovers a broad array of topics on outcomes- and value-based RWE assessments Demonstrates proper Bayesian application and causal inference for real-world data (RWD)Presents real-world use cases to illustrate the use of advanced analytics and statistical methods to generate insightsOffers a balanced discussion of practical RWE issues at hand and technical solutions suitable for practitioners with limited data science expertise This book concerns use of real world data (RWD) and real world evidence (RWE) to aid drug development across product cycle. RWD are healthcare data that are collected outside the constraints of conventual controlled randomized trials (CRTs); whereas RWE is the knowledge derived from aggregation and analysis of RWD. Shipping may be from our Sydney, NSW warehouse or from our UK or US warehouse, depending on stock availability.